Buprenorphine-naloxone versus methadone maintenance therapy: A randomised double-blind trial with opioid-dependent patients

Heroin Addiction and Related Clinical Problems

Volumn 10, Issue 4, 2008, Pages 5-18

  Kamien, Jonathan B ^a,b   Branstetter, Steven A ^a,c   Amass, Leslie ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b BioPsych Consulting   (United States)

^c WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Buprenorphine; Buprenorphine naloxone (Suboxone ); Methadone; Opioid dependence; Treatment outcome

Indexed keywords

AMPHETAMINE; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; CANNABINOID; COCAINE; DIAMORPHINE; METHADONE; OPIATE; PLACEBO;

ABSTINENCE; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DEPENDENCE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PATIENT COUNSELING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; UNSPECIFIED SIDE EFFECT; URINALYSIS;

EID: 58349118732     PISSN: 15921638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. ACEIJAS C., STIMSON G.V., HICKMAN M., RHODES T., UNITED NATIONS REFERENCE GROUP ON HIV/AIDS PREVENTION AND CARE AMONG IDU IN DEVELOPING AND TRANSITIONAL COUNTRIES. (2004): Global overview of injecting drug use and HIV infection among injecting drug users. AIDS 18(17): 2295-2303.
2. AHAMADI J., BABAEE-BEIGI M., ALISHAHI M., MAANY I., HIDARI T. (2004): Twelve-month maintenance treatment of opium-dependent patients. J Subst Abuse Treat 26(1): 363-366.
3. AIKEN M. (1982): A program for balancing the allocation of subjects in a clinical trial. Comput Biomed Res 15(6): 519-524.
4. ALHO H., SINCLAIR D., VUROI E., HOLOPANINEN A. (2007): Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend 88(1): 75-78.
5. AMASS L., BICKEL W.K., CREAN J.P., BLAKE J., HIGGINS S.T. (1998): Alternate-day buprenorphine dosing is preferred to daily dosing by opiate-dependent humans. Psychopharmacology (Berl) 136(3): 217-225.
6. AMASS L., BICKEL W.K., HIGGINS S.T., HUGHES J.R. (1994): A preliminary investigation of outcome following gradual or rapid buprenorphine detoxification. J Addict Dis 13(3): 33-45.
7. AMASS L., KAMIEN J.B., MIKULICH S.K. (2001): Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans. Drug Alcohol Depend 61(2): 173-181.
8. AMASS L., KAMIEN J.B., MIKULICH S.K. (2000): Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet. Drug Alcohol Depend 58(1-2): 143-152.
9. AMASS L., KAMIEN J.B., REIBER C., BRANSTETTER S. (2000): Abuse liability of IV buprenorphine-naloxone, buprenorphine and hydromorphone in buprenorphinenaloxone maintained volunteers. Drug Alcohol Depend 60(suppl 1): S6.
10. AMASS L., LING W., FREESE T.E., REIBER C., ANNON J.J., COHEN A.J., MCCARTY D., REID M.S., BROWN L.S., CLARK C., ZIEDONIS D.M., KREJCI J., STINE S., WINHUSEN T., BRIGHAM G., BABCOCK D., MUIR J.A., BUCHAN B.J., HORTON T. (2004): Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience. Am J Addict 13(suppl 1): S42-S66.
11. BALL J.C., ROSS A (1991): The Effectiveness of Methadone Maintenance Treatment. Springer-Verlag, New York.
12. BELL J., BYRON G., GIBSON A., MORRIS A. (2004): A pilot study of buprenorphine-naloxone combination tablet (Suboxone®) in treatment of opioid dependence. Drug Alcohol Rev 23(3): 311-317.
13. BICKEL W.K., AMASS L. (1995): Buprenorphine treatment of opiate dependence: a review. Exp Clin Psychopharmacol (Berl) 3(4): 477-489.
14. BICKEL W.K., AMASS L., CREAN J.P., BADGER G.J. (1999): Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients. Psychopharmacology (Berl) 146(2): 111-118.
15. CARRIERI M.P., AMASS L., LUCAS G.M., VLAHOV D., WODAK A., WOODY G.E. (2006): Buprenorphine use: the international experience. Clin Infect Dis 43(suppl 4): S197-S215.
16. CHIANG C.N., BRIDGE P., HAWKS R.L., HERBERT S., HILL J., MAGHRABLIAN L., et al. (1996): The development of buprenorphine-naloxone products for treating opiate dependence. In: Harris LS, editor. Problems of Drug Dependence 1995: Proceedings of the 57th Annual Scientific Meeting of the College on Problems of Drug Dependence, Inc. NIDA Research Monograph No. 162; National Institute on Drug Abuse: Rockville, Maryland, p. 117.
17. CHIANG C.N., HAWKS R. (1994): Development of a buprenorphine-naloxone combination drug for the treatment of drug addiction. In: Harris LS, editor. Problems of Drug Dependence 1993: Proceedings of the 55th Annual Scientific Meeting of the College on Problems of Drug Dependence, Inc. NIDA Research Monograph No. 141; National Institute on Drug Abuse: Rockville, Maryland, p. 458.
18. COMER S.D., COLLINS E.D. (2002a): Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers. J Pharmacol Exp Ther 303(2): 695-703.
19. COMER S.D., COLLINS E.D., FISCHMAN M.W. (2002b): Intravenous buprenorphine self-administration by detoxified heroin abusers. J Pharmacol Exp Ther 301(1): 266-276.
20. DORAN C., HOLMES J., LADEWIG D., LING W. (2005): Buprenorphine induction and stabilisation in the treatment of opiate dependence. Heroin Addict Rel Clin Probl 7(1): 7-18.
21. DORAN C.M. (2005): Buprenorphine, buprenorphinenaloxone, and methadone maintenance: a cost-effectiveness analysis. Expert Rev Pharmacoeconomics Outcomes Res 5: 583-591.
22. DORAN C.M., SHANAHAN M., MATTICK R.P., ALI R., WHITE J., BELL J. (2003): Buprenorphine versus methadone maintenance: a cost-effectiveness analysis. Drug Alcohol Depend 71(3): 295-302.
23. EDER H., FISCHER G., GOMBAS W., JAGSCH R., STÜHLINGER G., KASPER S. (1998): Comparison of buprenorphine and methadone maintenance in opiate addicts. Eur Addict Res 4(suppl 1): 3-7.
24. EMCDDA (European Monitoring Centre for Drugs and Drug Addiction). (2006): The state of the Drugs problem in Europe. Lisbon: EMCDDA.
25. FIELLIN D.A., PANTALON M.V., CHAWARSKI M.C., MOORE B.A., SULLIVAN L.E., O'CONNOR P.G., SCHOTTENFELD R.S. (2006): Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med 355(4): 365-374.
26. FINCH J.W., KAMIEN J.B., AMASS L. (2007): Two-year experience with buprenorphine-naloxone (Suboxone®) for maintenance treatment of opioid-dependence within a private practice setting. J Addict Med 1(2): 104-110.
27. FISCHER G., GOMBAS W., EDER H., JAGSCH R., PETERNELL A., STÜHLINGER G., PEZAWAS L., ASCHAUER H.N., KASPER S. (1999): Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction 94(9): 1337-1347.
28. FISCHER G., ORTNER R., ROHRMEISTER K., JAGSCH R., BAEWERT A., LANGER M., ASCHAUER H. (2006): Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction 101(2): 275-281.
29. FUDALA P.J., BRIDGE T.P., HERBERT S., WILLIFORD W.O., CHIANG C.N., JONES K., COLLINS J., RAISCH D., CASADONTE P., GOLDSMITH R.J., LING W., MALKERNEKER U., MCNICHOLAS L., RENNER J., STINE S., TUSEL D., BUPRENORPHINE/NALOXONE COLLABORATIVE STUDY GROUP. (2003): Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 349(10): 949-958.
30. FUDALA P.J., YU E., MACFADDEN W., BOARDMAN C., CHAING N.C. (1998): Effects of buprenorphine and naloxone in morphine-stabilized opiate addicts. Drug Alcohol Depend 50(1): 1-8.
31. GERRA G., BORELLA F., ZAIMOVIC A., MOI G., BUSSANDRI M., BUBICI C., BERTACCA S. (2004): Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. Drug Alcohol Depend 75(1): 37-45.
32. GIACOMUZZI S.M., RIEMER Y., ERTL M., KEMMLER G., ROSSLER H., HINTERHUBER H., KURZ H. (2003): Buprenorphine versus methadone maintenance treatment in an ambulant setting: a health-related quality of life assessment. Addiction 98(5): 693-702.
33. HARRIS D.S., JINES R.T., WELM S., UPTON R.A., LIN E., MENDELSON J. (2000): Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. Drug Alcohol Depend 61(1): 85-94.
34. HUDZIAK J.J., HELZER J.E., WETZEL M.W., KESSEL K.B., MCGEE B., JANCA A., PRZYBECK T. (1993): The use of the DSM-III-R checklist for initial diagnostic assessments. Compr Psychiatry 34(6): 375-383.
35. JOHNSON R.E., CHUTUAPE M.A., STRAIN E.C., WALSH S.L., STITZER M.L., BIGELOW G.E. (2000): A comparison of levomethadyl acetate, buprenorphine and methadone for opioid dependence. N Engl J Med 343(18): 1290-1297.
36. JOHNSON R.E., JAFFE J.H., FUDALA P.J. (1992): A controlled trial of buprenorphine treatment for opiate dependence. JAMA 267(20): 2750-2755.
37. JOHNSON R.E., STRAIN E.C., AMASS L. (2003): Buprenorphine: how to use it right. Drug Alcohol Depend 70 (2 suppl): S59-S77.
38. KAKKO J., SVANBORG K.D., KREEK M.J., HEILIG M. (2003): 1-Year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomized, placebo-controlled trial. Lancet 361(9358): 662-668.
39. KAKKO J., GRÖNBLADH L., SVANBORG K.D., VON WACHENFELDT J., RÜCK C., RAWLING B., NILSSON L.H., HEILIG M. (2007): A stepped care strategy utilizing buprenorphine and methadone vs. conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am J Psychiatry 164(5): 797-803.
40. KAMIEN J.B., BRANSTETTER S.A., MIKULICH S.K., AMASS L. (2000): Impact of contingent takehomes and blind dose increases during buprenorphinenaloxone tablet and methadone maintenance treatment. In: Harris LS, editor. Problems of Drug Dependence 1999: Proceedings of the 61st Annual Scientific Meeting of the College on Problems of Drug Dependence, Inc. NIDA Research Monograph 180; U.S. Government Printing Office, Washington, DC.
41. KOSTEN T.R., SCHOTTENFELD R., ZIEDONIS D., FALCIONI J. (1993): Buprenorphine versus methadone maintenance for opiate dependence. J Nerv Ment Dis 181(6): 358-364.
42. LING W., AMASS L., SHOPTAW S., ANNON J.A., BABCOCK D., BRIGHAM, G., HARRER J., REID M., MUIR J., BUCHAN B., ORR D., WOODY G., KREJCI J., ZIEDONIS D., BUPRENORPHINE STUDY PROTOCOL GROUP. (2005): A multicenter randomized trial of buprenorphine-naloxone and clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction 100(8): 1090-1100.
43. LING W., WESSON D.R. (2003): Clinical efficacy of buprenorphine: comparisons to methadone and placebo. Drug Alcohol Depend 70(2 suppl): S49-S57.
44. LING W., WESSON D.R., CHARUVASTRA C., KLETT C.J. (1996): A controlled trial comparing buprenorphine and methadone maintenance in opiate dependence. Arch Gen Psychiatry 53(5): 401-407.
45. MAREMMANI I., PANI P.P., PACINI M., PERUGI G. (2007): Substance abuse and quality of life over 12 months among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patients. J Subst Abuse Treat 33(1): 91-98.
46. MATTICK R.P., BREEN C., KIMBER J., DAVOLI M. (2003): Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2: CD002209.
47. MCLELLAN A.T., LUBORSKY L., CACCIOLA J., GRIFFITH J., EVANS F., BARR H.L., O'BRIEN C.P. (1985): New data from the Addiction Severity Index: reliability and validity in three centers. J Nerv Ment Dis 173(7): 412-423.
48. MENDELSON J., JONES R.T., FERNANDEZ I., WELM S., MELBY A.K., BAGGOTT M.J. (1996): Buprenorphine and naloxone interactions in opiate-dependent volunteers. Clin Pharmacol Ther 60(1): 105-114.
49. PETITJEAN S., STOHLER R., DÉGLON J.J., LIVOTI S., WALDVOGEL D., UEHLINGER C., LADEWIG D. (2001): Double-blind randomized trial of buprenorphine and methadone in opiate dependence. Drug Alcohol Depend 62(1): 97-104.
50. PICKWORTH W.B., JOHNSON R.E., HOLICKY B.A., CONE E.J. (1993): Subjective and physiologic effects of intravenous buprenorphine in humans. Clin Pharmacol Ther 53(5): 570-576.
51. RAUDENBUSH S.W., XIAO-FENG L. (2001): Effects of study duration, frequency of distribution and sample size on power in studies of group differences in polynomial change. Psychol Methods 6(4): 387-401.
52. SAMHSA (Substance Abuse and Mental Health Services Administration). (2004a): Overview of Findings from the 2003 National Survey on Drug Use and Health. Office of Applied Studies, NSDUH Series H-24, DHHS Publication No. SMA 04-3963; Rockville, Maryland.
53. SAMHSA (Substance Abuse and Mental Health Services Administration), Office of Applied Studies. (2004b): Treatment Episode Data Set (TEDS): 1992-2002. National Admissions to Substance Abuse Treatment Services, DASIS Series: S-23, DHHS Publication No. (SMA) 04-3965; Rockville, Maryland.
54. SCHOTTENFELD R.S., CHAWARSKI M.C., PAKES J.R., PANTALON M.V., CARROLL K.M., KOSTEN T.R. (2005): Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence. Am J Psychiatry 162(2): 340-349.
55. SCHOTTENFELD R.S., CHAWARSKI M.C., MAZLAN M. (2008): Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial. Lancet 371(9631): 2192-200.
56. SCHOTTENFELD R.S., PAKES J.R., OLIVETO A., ZIEDONIS D., KOSTEN T.R. (1997): Buprenorphine versus methadone maintenance for concurrent opiate dependence and cocaine abuse. Arch Gen Psychiatry 54(8): 713-720.
57. STANTON A., MCLEOD C., KISSIN W., SONNENFELD J., LUCKEY J. (2006): Evaluation of the Buprenorphine Waiver Program: results from SAMHSA/CSAT's evaluation of the Buprenorphine Waiver Program. In: Harris LS, editor. Problems of Drug Dependence 2005: Proceedings of the 67th Annual Scientific Meeting of the College on Problems of Drug Dependence, Inc. NIDA Research Monograph 186; National Institute on Drug Abuse; Rockville, Maryland.
58. STOLLER K.B., BIGELOW G.E., WALSH S.L., STRAIN E.C. (2001): Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology (Berl) 154(3): 230-242.
59. STRAIN E.C., STITZER M.L., LIEBSON I.A., BIGELOW G.E. (1994): Comparison of buprenorphine and methadone in the treatment of opiate dependence. Am J Psychiatry 151(7): 1025-1030.
60. STRAIN E.C., STITZER M.L., LIEBSON I.A., BIGELOW G.E. (1993): Methadone dose and treatment outcome. Drug Alcohol Depend 33(2): 105-117.
61. STRAIN E.C., STOLLER K., WALSH, S.L., BIGELOW G.E. (2000): Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers. Psychopharmacology (Berl) 148(4): 374-383.
62. SULLIVAN L.E., BARRY D., MOORE B.A., CHAWARSKI M.C., TETRAULT J.M., PANTELON M.V., SCHOTTENFELD R.S., FIELLIN D.A. (2006): A trial of integrated buprenorphine/naloxone and HIV clinical care. Clin Infect Dis 43(suppl 4): S184-S190.
63. SULLIVAN L.E., CHAWARSKI M., O'CONNOR P.G., SCHOTTENFELD R.S., FIELLIN D.A. (2005): The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering treatment? Drug Alcohol Depend 79(1): 113-116.
64. UEHLINGER C., DÉGLON J., LIVOTI S., PETITJEAN S., WALDVOGEL D., LADEWING D. (1998): Comparison of buprenorphine and methadone in the treatment of opioid dependence. Swiss Multicentre Study. Eur Addict Res 4(suppl 1): 13-18.
65. WORLD HEALTH ORGANIZATION. (2007): WHO Model List of Essential Medicines 15th Edition [Online]. www.who.int/entity/medicines/publications/EML15.pdf.
66. YEH P.H., GAZDZINSKI S., DURAZZO T.C., SJÖSTRAND K., MEYERHOFF D.J. (2007): Hierarchical linear modeling (HLM) of longitudinal brain structures and cognitive changes in alcohol-dependent individuals during sobriety. Drug Alcohol Depend 91(2-3): 195-204.